Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Dig Liver Dis ; 54(1): 76-83, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34244110

ABSTRACT

BACKGROUND: Anti-TNFα represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs. AIMS: To assess the treatment patterns with the first anti-TNFα in IBD. METHODS: Retrospective, observational study. RESULTS: 310 IBD patients were analyzed along a 5-year follow-up period. 56.2% of Crohn's disease (CD) patients started with adalimumab (ADA), while 43.8% started with infliximab (IFX). 12.9% of ulcerative colitis (UC) patients initiated with ADA, while 87.1% initiated with IFX. Treatment intensification was required in 28.9% of CD and 37.1% of UC patients. Median time to treatment intensification was shorter in UC than in CD (5.3 vs. 14.3 months; p = 0.028). Treatment discontinuation due to reasons other than remission were observed in 40.7% of CD and 40.5% of UC patients, although, in UC patients there was a trend to lower discontinuation rates with IFX (36.6%) than with ADA (66.7%). Loss of response accounted for approximately one-third of discontinuations, in both CD and UC. CONCLUSIONS: Around one-third of IBD biologic-naive patients treated with an anti-TNFα required treatment intensification (earlier in UC) and around 40% discontinued the anti-TNFα due to inappropriate disease control.


Subject(s)
Adalimumab/therapeutic use , Colitis, Ulcerative/drug therapy , Crohn Disease/drug therapy , Infliximab/therapeutic use , Tumor Necrosis Factor Inhibitors/therapeutic use , Adult , Female , Follow-Up Studies , Humans , Induction Chemotherapy/statistics & numerical data , Male , Middle Aged , Retrospective Studies , Withholding Treatment/statistics & numerical data
2.
J Epidemiol Community Health ; 51(5): 526-30, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9425463

ABSTRACT

OBJECTIVE: To estimate the effectiveness of influenza vaccine in preventing hospital admission for pneumonia in non-institutionalised elderly people. DESIGN: This was a case-control study. SETTING: All three public hospitals in the Castellón area of Spain. PARTICIPANTS: Cases were people aged 65 or more not living in an institution who were admitted to hospital for pneumonia between November 15, 1994 and March 31, 1995. Each case was matched with two sex matched control subjects aged 65 years or older admitted to hospital in the same week for acute abdominal surgical conditions or trauma. The sampling of incident cases was consecutive. Eighty three cases and 166 controls were identified and included in the study. MEASUREMENTS: Trained interviewers completed a questionnaire for each subject on the vaccination status, smoking habits, previous diseases, health care use, social contacts, family background, the vaccination status of the family carer, home characteristics, and socioeconomic status. RESULTS: The adjusted odds ratio of the influenza vaccination preventing admission to hospital for pneumonia was 0.21 (95% confidence interval 0.09, 0.55). The variables which best explained the risk of being a case were age, intensity of social contacts, health care use, previous diseases, and the existence of a vaccinated family carer. CONCLUSIONS: Influenza vaccination reduced significantly hospital admissions for pneumonia in non-institutionalised elderly people.


Subject(s)
Influenza Vaccines , Patient Admission/statistics & numerical data , Pneumonia, Viral/prevention & control , Age Factors , Aged , Aged, 80 and over , Caregivers , Case-Control Studies , Female , Hospitals/statistics & numerical data , Humans , Male , Pneumonia, Viral/epidemiology , Risk Factors , Spain/epidemiology
3.
An Esp Pediatr ; 25(5): 363-6, 1986 Nov.
Article in Spanish | MEDLINE | ID: mdl-3028220

ABSTRACT

Authors report three cases of congenital mesoblastic nephroma. In two of them, diagnosis was neonatal, while the third was made at the 3rd-month. They discuss diagnostic procedures employed as well as pathological findings. Presence of a mass was the first clinical sign in all three cases. Nephrectomy was the only treatment employed, with favourable outcome.


Subject(s)
Kidney Neoplasms/congenital , Wilms Tumor/congenital , Female , Humans , Infant , Infant, Newborn , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/pathology , Male , Radiography , Wilms Tumor/diagnostic imaging , Wilms Tumor/pathology
5.
Chemotherapy ; 23 Suppl 1: 315-23, 1977.
Article in English | MEDLINE | ID: mdl-832530

ABSTRACT

Reference is made to the results obtained in 24 children, from 11 months to 12 years, affected with acute pneumopathies and treated with fosfomycin with a dosage of 200 mg/kg/day. In all cases a clinical, radiological, biological and bacteriological study was carried out. At the same time, levels of fosfomycin in plasma and sputum were checked every 5 days during the course of treatment. In the 4 cases of pleurisy the level of antibiotic in the pleural liquid was also checked. The concentration of fosfomycin in the sputum gives very variable results with average values oscillating between 16.5 and 23.4% of the plasmatic level respectively at the beginning and end of treatment, a cumulative effect of the antibiotic being observed. Concentration in pleural liquid oscillates between 39 and 50%. The clinical, radiological and biological evolution has been favourable iin 21 cases, unfavourable in two cases and in one case treatment had to be suspended because of the apparition of a cutaneous necrosis. Apart from this case no notable toxic effects were observed. Children do not support intramuscular injections very well and intravenous injections often cause phlebitis.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Fosfomycin/therapeutic use , Respiratory Tract Infections/drug therapy , Bronchitis/drug therapy , Child , Child, Preschool , Drug Evaluation , Fosfomycin/adverse effects , Fosfomycin/metabolism , Humans , Infant , Pleura/metabolism , Pleurisy/drug therapy , Pneumonia/drug therapy , Respiratory Tract Infections/metabolism , Sputum/analysis , Tracheitis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...